Becker's Healthcare December 18, 2025
Novo Nordisk is seeking FDA approval for an experimental obesity shot, CagriSema (cagrilintide and semaglutide), according to a Dec. 18 news release from the Denmark-based drugmaker.
CagriSema is a weekly injection of semaglutide, a GLP-1, and cagrilintide, a long-acting amylin analogue. If approved, the drug would be the first injectable GLP-1 and amylin analogue combination treatment.
In a phase 3 trial of 3,417 adults with obesity or overweight with at least one obesity-related complication, those who took CagriSema achieved an average weight loss of 20.4% after 68 weeks. The placebo group averaged a 3% reduction in weight, according to the release.
Novo Nordisk said it expects the FDA to review the CagriSema application in 2026.
Here...
Today's Sponsors
Today's Sponsor